Related Experiment Video
Updated: Oct 27, 2025

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
Published on: June 3, 2018
Interactions between the ERK1/2 signaling pathway and PCAF play a key role in PE‑induced cardiomyocyte hypertrophy
Qian Mao1, Shuqi Wu1, Chang Peng1
1Department of Pediatrics, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563000, P.R. China.
Insights
Phenylephrine (PE) induces cardiomyocyte hypertrophy via extracellular signal-regulated kinase (ERK)1/2 signaling, which interacts with PCAF to modify histone acetylation. Inhibiting ERK or histone acetylase prevents hypertrophy.
Area of Science:
- Cardiovascular Biology
- Epigenetics
- Molecular Cardiology
Background:
- Cardiomyocyte hypertrophy is a key factor in chronic heart failure.
- Extracellular signal-regulated protein kinase (ERK) signaling is crucial for cardiomyocyte hypertrophy.
- Previous studies linked phenylephrine (PE)-induced hypertrophy to histone H3K9ac hyperacetylation by PCAF, but upstream pathways remained unclear.
Purpose of the Study:
- To investigate the role of the ERK1/2 signaling pathway in PE-induced cardiomyocyte hypertrophy.
- To elucidate the interaction between ERK1/2, PCAF, and histone H3K9ac acetylation in this process.
Main Methods:
- Established a mouse cardiomyocyte hypertrophy model using PE treatment in vitro.
- Utilized an ERK inhibitor (U0126) and a histone acetylase inhibitor (anacardic acid; AA).
- Assessed the interaction of phospho-ERK1/2 with PCAF and changes in H3K9ac acetylation patterns.
Main Results:
- Phospho-ERK1/2 was found to interact with PCAF, altering H3K9ac acetylation.
- U0126 and/or AA treatment attenuated phospho-ERK1/2 and H3K9ac overexpression by inhibiting PCAF expression.
- Inhibitors reduced the expression of cardiac hypertrophy biomarker genes and prevented hypertrophy.
Conclusions:
- Revealed a novel mechanism where anacardic acid protects against PE-induced cardiomyocyte hypertrophy via the ERK1/2 pathway and H3K9ac modification.
- Findings suggest potential therapeutic strategies for hypertrophic cardiomyopathy by targeting ERK1/2 and histone acetylation.
Abstract:
Cardiomyocyte hypertrophy is a compensatory phase of chronic heart failure that is induced by the activation of multiple signaling pathways. The extracellular signal‑regulated protein kinase (ERK) signaling pathway is an important regulator of cardiomyocyte hypertrophy. In our previous study, it was demonstrated that phenylephrine (PE)‑induced cardiomyocyte hypertrophy involves the hyperacetylation of histone H3K9ac by P300/CBP‑associated factor (PCAF). However, the upstream signaling pathway has yet to be fully identified. In the present study, the role of the extracellular signal‑regulated protein kinase (ERK)1/2 signaling pathway in PE‑induced cardiomyocyte hypertrophy was investigated. The mice cardiomyocyte hypertrophy model was successfully established by treating cells with PE in vitro. The results showed that phospho‑(p‑)ERK1/2 interacted with PCAF and modified the pattern of histone H3K9ac acetylation. An ERK inhibitor (U0126) and/or a histone acetylase inhibitor (anacardic acid; AA) attenuated the overexpression of phospho‑ERK1/2 and H3K9ac hyperacetylation by inhibiting the expression of PCAF in PE‑induced cardiomyocyte hypertrophy. Moreover, U0126 and/or AA could attenuate the overexpression of several biomarker genes related to cardiac hypertrophy (myocyte enhancer factor 2C, atrial natriuretic peptide, brain natriuretic peptide and β‑myosin heavy chain) and prevented cardiomyocyte hypertrophy. These results revealed a novel mechanism in that AA protects against PE‑induced cardiomyocyte hypertrophy in mice via the ERK1/2 signaling pathway, and by modifying the acetylation of H3K9ac. These findings may assist in the development of novel methods for preventing and treating hypertrophic cardiomyopathy.
More Related Videos
08:00Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
Published on: July 10, 2019
08:03Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
Published on: October 20, 2022
Related Concept Videos
cAMP-dependent Protein Kinase Pathways
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
MAPK Signaling Cascades
Amplifying Signals via Enzymatic Cascade
Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
GPCRs Regulate Adenylyl Cylase Activity